Oxaliplatin

Product: 
Oxaliplatin
Formalary: 
Specialty Formalary
Category: 
Oncology
Trade Name: 
Eloxatin
Packing: 
Injection
Potency: 
100mg/20ml, 50mg/10ml
In Treatment of: 
OXALIPLATIN is a platinum-based drug used in combination with infusional 5-fluorouracil /leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. Treatment of advanced colorectal cancer.
Adverse Effects: 
Most common adverse reactions (incidence ≥ 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. Other adverse reactions, including serious adverse reactions, have been reported
Contraindication: 
Known allergy to OXALIPLATIN or other platinum compounds
Special Precaution: 
Allergic Reactions: Monitor for development of rash, urticaria, erythema, pruritis, bronchospasm, and hypotension. Neuropathy: Reduce the dose or discontinue OXALIPLATIN if necessary. Pulmonary Toxicity: May need to discontinue OXALIPLATIN until interstitial lung disease or pulmonary fibrosis are excluded. Hepatotoxicity: Monitor liver function tests. Pregnancy. Fetal harm can occur when administered to a pregnant woman. Women should be apprised of the potential harm to the fetus.
Interaction: 
No specific cytochrome P-450-based drug interaction studies have been conducted. No pharmacokinetic interaction between 85 mg/m2 OXALIPLATIN and 5-fluorouracil/leucovorin has been observed in patients treated every 2 weeks. Increases of 5-fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 OXALIPLATIN dosed every 3 weeks. Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this has not been specifically studied
Dosages: 
Administer OXALIPLATIN in combination with 5-fluorouracil/leucovorin every 2 weeks.: Day 1: OXALIPLATIN 85 mg/m2 intravenous infusion in 250–500 mL 5% Dextrose Injection, USPand leucovorin 200 mg/m2 intravenous infusion in 5% Dextrose Injection, USP both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2–4 minutes, followed by 5-fluorouracil 600 mg/m2 intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion. Day 2: leucovorin 200 mg/m2 intravenous infusion over 120 minutes, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2–4 minutes, followed by 5-fluorouracil 600 mg/m2 intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion. Reduce the dose of OXALIPLATIN to 75 mg/m2 (adjuvant setting) or 65 mg/m2 (advanced colorectal cancer): if there are persistent grade 2 neurosensory events that do not resolve. after recovery from grade 3/4 gastrointestinal toxicities (despite prophylactic treatment) or grade 4 neutropenia or grade 3/4 thrombocytopenia. Delay next dose until neutrophils ≥1.5 × 109/L and platelets ≥75 × 109/L. For patients with severe renal impairment (creatinine clearance <30 mL/min), the initial recommended dose is 65 mg/m2. Discontinue OXALIPLATIN if there are persistent Grade 3 neurosensory events. Never reconstitute or prepare final dilution with a sodium chloride solution or other chloride-containing solutions.

Share Us